PHILADELPHIA – Fox Chase Cancer Center researchers have found that inhibiting an enzyme critical to cancer cell repair and proliferation may represent a new potential strategy for treating melanoma. Their paper, entitled, “Thymine DNA glycosylase as a novel target for melanoma,” appears in the journal Oncogene.

“Melanoma is classified as a ‘recalcitrant cancer’ by the National Cancer Institute because it can be difficult to treat in its advanced stages due to drug resistance,” said Alfonso Bellacosa, MD, PhD, a professor of cancer epigenetics at Fox Chase, and senior author of the study. “Until check-point inhibitor immunotherapy became available, we had seen little advancement in therapeutic approaches, and new targets are urgently needed.” Leading authors of the study are Pietro Mancuso PhD and Rossella Tricarico PhD….More>>